Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro
about
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionClinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyApproved Antiviral Drugs over the Past 50 YearsProfile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDSA cutting-edge view on the current state of antiviral drug development.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionA high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.Overcoming pharmacologic sanctuaries.Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal ImpairmentCobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.Cobicistat : a new opportunity in the treatment of HIV disease?Pharmacokinetic enhancers in HIV therapeutics.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.Darunavir/cobicistat once daily for the treatment of HIV.Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.The role of tenofovir alafenamide in future HIV management.Renal effects of novel antiretroviral drugs.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapyCobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study.Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
P2860
Q26750406-D42831A1-5C05-4476-A1FD-FA06DEFCBB3CQ26771182-638A8CC9-1C6A-451A-A8EC-3126BE823F77Q27755387-A5495BEA-F910-4954-9D21-D947EBFFA944Q28073206-9218D068-A676-4DB6-B627-7272E5B3401CQ34036018-79AF0496-54BC-4AC3-8203-44345428AE5EQ34736194-68E308E2-ADEB-4814-97DF-FEEACBB108DDQ34976284-CD310260-3B31-4742-9510-5A277CEF0C64Q34977187-3B5E2205-AB99-4761-9CBB-E6CEFF7F1088Q35567828-7F8C7A98-D969-406B-9A53-A4EB0428AF72Q36072448-D2E253F6-1BCF-4D72-AA32-DBBA6DFD6F8BQ36219963-117ABF67-71F6-4380-B889-951E45A0EFCFQ36915933-1FF26000-753A-4800-BD8F-B66AD9373D92Q37203743-92F20597-7937-4860-9FAC-8A16E862D717Q38171753-D3E1428F-02D2-40AC-8D3C-24683D32D198Q38211165-1ED61902-AE64-41C7-A6E3-A6926414A553Q38244014-BEDFF1E3-C861-4BCF-B95A-25F9C1BD5040Q38247035-8CBDE11F-1F52-4FB4-93E6-BC5FDE7FC306Q38305617-E3122EEA-B749-4CC4-AC93-79C781FCD2BBQ38472696-E65EFCB8-6951-4DF6-8C6B-10E18B240257Q38650067-C42F849A-AA3E-4B11-9E94-10018ACD75BAQ38661064-AFF7953D-20AA-4FA8-A0FC-216B893AB7A2Q38764695-B2E5A9BE-47E6-4686-9B87-6F773DA6596EQ38837077-437CF373-627D-435F-9C30-38DC7BA4687BQ38984695-9C3F3A4E-F0D4-4285-ABE4-C18CF03BF421Q38997526-454F4698-B00E-4AAC-A943-A11F7721DCFFQ39002230-68B9572C-AE3C-4127-932E-3C66DBCBD380Q39034742-441BF9D9-39E6-4579-AABA-ABF7ABDBA85EQ39118603-2070DC53-5DE8-4A67-9EF0-6EAD5B0A9230Q40077147-5204B280-FD50-4F55-B96F-5C7A6118520DQ40185119-30E8B337-D826-4943-B69B-EAB5002A2654Q40282068-35D50DC1-65E6-45D3-B965-2092F1F34A88Q40676324-E5D88056-8C36-4938-B516-93F156EABAD8Q40766725-EEF210F0-AA93-45AC-A6A8-DA4C316A1471Q41643193-292FC479-50DC-4177-B414-C20B56B01F34Q43013478-E8138905-B11F-4C33-963D-1795FF215293Q45961010-FC3A760E-0FAC-4849-B602-9CF76E6DA097Q47806688-8C559530-BB3D-4AB0-9FAA-CF742CEBB09DQ51750715-2A356601-95E2-4068-80A5-86C6DA8294E7Q52729705-6DB863E4-FA5F-43FE-92E4-D2F0C652F3FFQ59126145-876C01FD-F754-468C-9633-105D12B2DA36
P2860
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@ast
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@en
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@nl
type
label
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@ast
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@en
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@nl
prefLabel
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@ast
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@en
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@nl
P2093
P2860
P3181
P356
P1476
Cobicistat boosts the intestin ...... hibitors and GS-7340, in vitro
@en
P2093
Anupma Roy
Bernard Murray
Eve-Irene Lepist
Kelly Maclennan
Truc K Phan
P2860
P304
P3181
P356
10.1128/AAC.01089-12
P407
P577
2012-10-01T00:00:00Z